Pharma Business - July 3, 2020
Selumetinib granted orphan drug designation in Japan for NF1
AstraZeneca’s Selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1). Selumetinib is co-developed and co-commercialised with MSD. “Neurofibromatosis type 1 can have a devastating impact on children and new medicines are urgently needed to help treat the resulting plexiform neurofibromas and associated clinical issues. Current options […]
Collaboration - June 25, 2020
BioVentureHub and Mölnlycke collaborate
AstraZeneca’s BioVentureHub has established a new collaboration with medtech company Mölnlycke to support knowledge exchange across the Swedish life science industry. Small and medium-sized enterprises (SMEs) connected to AstraZeneca’s BioVentureHub will be offered free consultations with Mölnlycke experts with regard to developing products and solutions featuring medical device components. “With increasing focus on precision medicine, […]
Clinical Trials - June 15, 2020
AstraZeneca to supply Europe with up to 400 million vaccine doses
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine, with deliveries starting by the end of 2020. With the agreement, the IVA aims to accelerate the supply of the vaccine and […]
Acquisition - June 7, 2020
Potential merger between AstraZeneca and Gilead
AstraZeneca has made a preliminary approach to Gilead Sciences about a potential merger, according to Bloomberg. AstraZeneca informally contacted Gilead last month to gauge its interest in a possible tie-up asking not to be identified because the details are private, reports Bloomberg. AstraZeneca didn’t specify terms for any transaction, they said. No decisions have been […]
COVID-19 - June 5, 2020
AstraZeneca in agreements to enable global access to COVID-19 vaccine
AstraZeneca has taken the next steps in its commitment to global access to the University of Oxford’s COVID-19 vaccine, following agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII). “We are working tirelessly to honor our commitment to ensure broad and equitable access to […]
Collaboration - June 4, 2020
AstraZeneca collaborates with Accent Therapeutics
AstraZeneca will collaborate with Accent Therapeutics to discover, develop and commercialize transformative therapeutics targeting RNA-modifying proteins (RMPs) for the treatment of cancer. This collaboration focuses on targeting RMPs, proteins that control many aspects of RNA biology and represents a new approach for addressing the process disruptions that can lead to cancer and can cause resistance […]
